Get the Stockscreener App
2.26
3.83%
-0.09
Pre-market:
2.27
0.01
+0.44%
Soligenix Inc Stock (SNGX) Latest News
Soligenix Advances Innovative Treatments for Rare Diseases - citybuzz -
Soligenix Aims To Push The Boundaries In Treating Rare Diseases - Nasdaq
TALTZ’s Rapid Market Ascent Reflects its Unparalleled Ability to Transform the Treatment Landscape for Autoimmune Diseases | DelveInsight - GlobeNewswire Inc.
Soligenix's Leadership Aims To Drive Growth In Rare Disease Markets In 2025 And 2026 - The Globe and Mail
SoundHound AI Stock at a Crossroads—Is a Bottom in Sight? - The Globe and Mail
Soligenix settles debt with Pontifax lenders - MSN
Soligenix, Inc. Repays and Terminates Loan Agreement with Pontifax Medison FinanceOn February 5, 2025, Soligenix, Inc. (NASDAQ:SNGX) announced in an SEC Filing the full repayment and termination of all outstanding obligations under the Loan and Se - Defense World
Soligenix Repays Loan, Boosting Financial Flexibility - TipRanks
Soligenix on Way to Bio Conference in NYC - Baystreet.ca
Rare Disease Pioneer Soligenix Takes Center Stage at Major Biotech Investor Summit - StockTitan
Symbol Lookup - GuruFocus.com
SPI Energy and Soligenix Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV - ACCESS Newswire
Soligenix and Sharps Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - ACCESS Newswire
Soligenix (NASDAQ:SNGX) & Rhythm Pharmaceuticals (NASDAQ:RYTM) Head to Head Contrast - Defense World
Soligenix (SNGX) Stock Price, News & Analysis - MarketBeat
Soligenix (NASDAQ: $SNGX) Unveils Two-Pronged Approach To Tackle Rare Diseases & Unmet Medical Needs - MSN
Soligenix to Present at Upcoming Investor Conferences - PR Newswire
Soligenix to Present at Two Major Investor Conferences in January 2024 - StockTitan
Stock market today: Phio Pharmaceuticals -20.76%, Soligenix -20.15% among biggest losers in early trading - Business Upturn
SNGX: Additional Positive Outcomes in Investigator-Initiated Study of HyBryte in CTCL… - MSN
EXCLUSIVE: Soligenix's Cancer Candidate Shows Encouraging Action With Extended Treatment At One Year - AOL
SNGX: Additional Positive Outcomes in Investigator-Initiated Study of HyBryte in CTCL - Smartkarma
Soligenix's HyBryte Shows 70% Success Rate in CTCL Treatment Study, Complete Response in Some Patients - StockTitan
Cutaneous T-cell Lymphoma Market on Track for Major Expansion - openPR
Soligenix, and Graphex Group Interviews to Air on Bloomberg TV on the RedChip Money Report(R) - StockTitan
Soligenix Advances Treatment for Rare Skin Cancer with HyBryte - Citybuzz
Soligenix begins enrolling subjects in cutaneous T-cell lymphoma treatment trial - Yahoo Finance
Soligenix Reports It Is On Cusp Of Treating Rare Cancer CTCL - Nasdaq
Soligenix initiates confirmatory Phase 3 trial of HyBryte - Yahoo Finance
SNGX: Phase 3 FLASH2 Trial of HyBryte in CTCL Underway - Smartkarma
EXCLUSIVE: Soligenix Starts Confirmatory Late-Stage Trial For HyBryte For Type Of Blood Cancer - AOL
SNGX: Phase 3 FLASH2 Trial of HyBryte in CTCL Underway… - Zacks Small Cap Research
Soligenix, Inc. Initiates Confirmatory Phase 3 Clinical Trial of HyBryte for the Treatment of Cutaneous T-Cell Lymphoma - Marketscreener.com
Soligenix Initiates Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma - PR Newswire
Oral Mucositis Market expected to rise | Companies- Galera Therapeutics, Soligenix, Izun Pharma, MitoImmune Therapeutics, Tosk, Cellix Bio, Enzychem Lifesciences, Monopar Therapeutics - The Globe and Mail
Winter 2024 Investor Summit Virtual: Q4 Presentations Now Available for On-Demand Viewing - AccessWire
Soligenix's HyBryte™ Shows 3x Better Response Rate vs Valchlor® in Rare Disease Trial - StockTitan
HyBryte™ Clinical Results Demonstrate Continued Improvement Post-Treatment - The Malaysian Reserve
Soligenix (STU:DOA) 3-Year Revenue Growth Rate : 0.00% (As of Sep. 2024) - GuruFocus.com
Soligenix, A Pharmaceutical Firm Tackling Potentially Lucrative Unmet Medical Needs - Nasdaq
Soligenix Advances Promising Treatments for Rare Diseases and Public Health Threats - Citybuzz
Soligenix Announces Recent Accomplishments And Third Quarter 202 - GuruFocus.com
Soligenix Initiates a Phase 2 Clinical Trial of SGX945 (dusqueti - GuruFocus.com
Soligenix Launches European Advisory Board for Phase 3 HyBryte CTCL Trial - Dermatology Times
Soligenix Announces Formation of European Medical Advisory Board for Cutaneous T-Cell Lymphoma - PR Newswire
Soligenix Trumpets Q2 Numbers - MENAFN.COM
Soligenix to Present at Q4 Investor Summit: Rare Disease Treatment Pipeline in Focus | SNGX Stock News - StockTitan
Brokers Offer Predictions for Soligenix FY2024 Earnings - Defense World
Soligenix Initiates a Phase 2 Clinical Trial of SGX945 (dusquetide) for the treatment of Behçet's Disease - The Malaysian Reserve
0.53%
0.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):